3 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
Primary ObjectivesThe primary objectives of the study are:· To determine the efficacy of Epanova 2 g daily compared to olive oil 2 g daily for 12 weeks in lowering serum TG levels in subjects with severehypertriglyceridemia (TG levels *500 mg/dL [5.…
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…